GlassScriptPhysician profile
Yamin Sun
NPI 1801216080
$17,417.24
in general payments reported to CMS, 2019-2025
71 companies · $2,560 in 2025
The $2,560 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $855 · 2020: $1,045 · 2021: $2,869 · 2022: $3,281 · 2023: $3,320 · 2024: $3,487 · 2025: $2,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,096 · Education: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,096.23 |
| Education | $271.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,408.14 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $986.68 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $933.06 | 2020-2025 | Enhertu, Lynparza, Tagrisso |
| Celgene Corporation | $841.93 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Exelixis INC. | $841.10 | 2019-2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $758.28 | 2020-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $745.92 | 2019-2025 | Talvey, Darzalex, Tecvayli |
| Genentech USA, INC. | $710.01 | 2019-2025 | Venclexta, Tecentriq, Alecensa |
| Incyte Corporation | $700.75 | 2020-2025 | Jakafi, Monjuvi |
| Seagen INC. | $687.42 | 2020-2023 | Adcetris, Padcev, Tukysa |
| Pfizer INC. | $685.53 | 2020-2025 | |
| Daiichi Sankyo INC. | $646.83 | 2020-2025 | Enhertu, Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $468.55 | 2019-2025 | |
| Eisai INC. | $455.27 | 2020-2025 | |
| Abbvie INC. | $433.33 | 2020-2025 | Venclexta |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $431.44 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $407.30 | 2021-2025 | Ninlaro, Iclusig, Alunbrig |
| Amgen INC. | $358.39 | 2020-2023 | Nplate, Xgeva, Vectibix |
| Genzyme Corporation | $347.47 | 2020-2025 | |
| Jazz Pharmaceuticals INC. | $332.36 | 2020-2025 | Zepzelca |
| Gilead Sciences, INC. | $295.59 | 2021-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $287.83 | 2021-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $255.21 | 2020-2023 | Imbruvica |
| Lilly USA, LLC | $248.20 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Rigel Pharmaceuticals, INC. | $206.36 | 2020-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Tersera Therapeutics LLC | $195.50 | 2020-2025 | Zoladex |
| Astellas Pharma US INC | $180.62 | 2020-2024 | Padcev, Xospata |
| Coherus Oncology, INC. | $151.36 | 2020-2024 | |
| Puma Biotechnology, INC. | $129.98 | 2021-2025 | |
| Aveo Pharmaceuticals, INC. | $129.88 | 2021-2024 | Fotivda |
| Servier Pharmaceuticals LLC | $116.40 | 2021-2025 | |
| Array Biopharma INC | $112.19 | 2021-2025 | Mektovi, Braftovi, Lorbrena |
| Deciphera Pharmaceuticals INC. | $111.67 | 2021-2025 | Qinlock, Romvimza |
| Alexion Pharmaceuticals, INC. | $107.83 | 2021-2024 | Ultomiris |
| Emd Serono, INC. | $102.59 | 2020-2025 | |
| Pharmaessentia USA Corporation | $90.42 | 2024-2025 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.54 | 2022-2023 | Gilotrif |
| Octapharma USA, INC. | $86.34 | 2021 | |
| Acrotech Biopharma INC. | $81.42 | 2021-2024 | Beleodaq |
| Beigene USA, INC. | $76.11 | 2020-2024 | Brukinsa |
| Morphosys, US INC. | $73.85 | 2021-2023 | Monjuvi |
| Sumitomo Pharma America, INC. | $68.31 | 2023-2024 | Orgovyx |
| Epizyme, INC. | $65.86 | 2022 | |
| Caris Mpi, INC. | $63.93 | 2025 | Mi Cancer Seek |
| Beone Medicines USA, INC. | $63.18 | 2025 | Tevimbra |
| Acceleron Pharma, INC. | $57.98 | 2020-2021 | |
| Adc Therapeutics America, INC. | $56.60 | 2021-2025 | |
| Dova Pharmaceuticals | $55.10 | 2021 | |
| Tempus Ai, INC | $51.74 | 2024 | |
| Stemline Therapeutics INC. | $50.48 | 2024-2025 | Orserdu |
| Sun Pharmaceutical Industries INC. | $50.32 | 2023-2024 | Yonsa, Odomzo |
| Sobi, INC | $43.86 | 2024-2025 | |
| Mirati Therapeutics, INC. | $43.67 | 2024 | Krazati |
| Taiho Oncology, INC. | $40.08 | 2020-2023 | |
| Karyopharm Therapeutics INC. | $39.26 | 2021-2023 | Xpovio |
| Blueprint Medicines Corporation | $38.98 | 2020-2022 | |
| Myovant Sciences INC. | $33.60 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $33.11 | 2021 | |
| Foundation Medicine, INC. | $30.13 | 2022 | |
| Azurity Pharmaceuticals, INC. | $26.25 | 2025 | Danziten |
| Tolmar, INC. | $25.94 | 2023 | |
| Immunogen, INC. | $24.28 | 2023 | Elahere |
| Heron Therapeutics, INC. | $20.76 | 2020 | |
| Legend Biotech USA INC. | $19.53 | 2025 | Carvykti |
| Janssen Pharmaceuticals, INC | $17.45 | 2025 | Erleada |
| Cti Biopharma Corp. | $16.71 | 2022 | |
| Agios Pharmaceuticals, INC. | $16.04 | 2021 | |
| Geron Corporation | $15.91 | 2025 | Rytelo |
| Kite Pharma, INC. | $14.90 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $14.66 | 2020 | |
| Amag Pharmaceuticals, INC. | $11.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yamin Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.